spacer
 
|

Improving Outcomes in CML:
A 2014 Update for Managed Care Healthcare Professionals

This activity is jointly provided by Global Education Group and ASiM.

Supported by an educational grant from Bristol-Myers Squibb Company.

What you are about to see is a previously recorded live webcast. Please note that only “home study” credit will be awarded for participating in this archived presentation. No “live” credits are available.

OVERVIEW
The advent of tyrosine kinase inhibitor (TKI) therapy has transformed the once fatal chronic myeloid leukemia (CML) into a manageable chronic malignancy, with a 10-year estimated all-cause mortality of a mere 2%. Monitoring patient response to TKI therapy is the cornerstone of managing patients with CML, and the assessment of molecular response to treatment at recommended time-intervals is an important milestone for predicting long-term treatment success. With treatment costing nearly $100 000 annually in the United States, assessing efficacy and adjusting management strategies is paramount to cost-effective treatment decisions. As drug therapy and medical experts play integral roles in managing patients with CML and, by promoting cost-effective therapy utilization, managed care pharmacists, specialty pharmacists, and medical directors are uniquely positioned to provide guidance and education regarding response assessment and therapeutic effectiveness. Knowing how to translate this wealth of information into clinical practice is crucial for improving patient and pharmacoeconomic outcomes.

GOAL
This archived webcast will provide the most current data on the management of patients with CML thus allowing managed care and specialty pharmacists and medical directors to improve patient and pharmacoeconomic outcomes.

INTENDED AUDIENCE
This archived webcast is designed for managed care and specialty pharmacists and medical directors. No prerequisites required.

LEARNING OBJECTIVES
Upon the conclusion of this activity, the participant should be able to:
  • OUTLINE NCCN guidelines for monitoring, testing, and assessing therapeutic effectiveness to CML therapies.
  • EVALUATE potential CML therapy adjustments based on time-based clinical responses.
  • ASSESS various CML therapeutic strategies based on pharmacogenetic markers.
  • DISTINGUISH toxicity profiles between available TKIs.

DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices that they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FACULTY
Chris Fausel, PharmD, MHA, BCOP (Course Director)
Clinical Manager, Oncology Pharmacy
Indiana University Health
Chair, Hoosier Oncology Group
Indianapolis, Indiana
Dr Fausel reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Joseph Bubalo, PharmD, BCPS, BCOP
Assistant Professor of Medicine
Oncology Clinical Specialist
Oregon Health & Science University
Hospital and Clinics
Portland, Oregon
Dr Bubalo reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

R. Donald Harvey, PharmD, FCCP, BCOP
Associate Professor, Hematology/Medical Oncology
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Atlanta, Georgia
Dr Harvey reports receiving research support from Bristol-Myers Squibb Company and Novartis.

Elias Jabbour, MD
Associate Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Dr Jabbour reports serving as a consultant for Arion Pharmaceuticals, Bristol-Myers Squibb Company, Novartis, Pfizer Inc, and Teva.

Jim A. Jorgenson, RPh, MS, FASHP
President, Hospitals & Health Systems
Visante, Inc
St. Paul, Minnesota
Dr Jorgenson reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Jolynn Sessions, PharmD, BCOP
Clinical Pharmacist Faculty in Oncology
Mission Health System and
UNC Eshelman School of Pharmacy
Asheville, North Carolina
Dr Sessions reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Joseph M. Sinopoli, RPh
President
PreLaunch Strategy, LLC
Boston, Massachusetts
Mr Sinopoli reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Andrea Funk and Ashley Marostica, RN, MSN (Global) report having no relevant financial or advisory relationships with corporate organizations related to this activity.

Amanda Glazar, PhD, CCMEP, (Global) reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Jessica Marshall, PhD, and Melinda Castro (ASiM) report having no relevant financial or advisory relationships with corporate organizations related to this activity.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and ASiM do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and ASiM. Global is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Global Education Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com.

Estimated time to complete this activity: 1.5 hours.

Release Date: January 5, 2015    Expiration Date: January 5, 2016

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AMERICANS WITH DISABILITIES ACT (ADA)
Global Education Group complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.

FEE INFORMATION
There is no fee for this educational activity.

SYSTEM REQUIREMENTS
PC: Microsoft Windows 2000 SE or above; Flash Player Plugin (v7.0.1.9 or greater); Internet Explorer (v5.5 or greater), or Firefox; Adobe Acrobat Reader*; MAC: MAC OS 10.2.8; Flash Player Plugin (v7.0.1.9 or greater); Safari; Adobe Acrobat Reader*.
*Internet Explorer is not supported on the Macintosh.

INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must complete the pre-test, listen to the following presentation, and complete the post-test and evaluation to receive CPE credit for this activity. A statement of credit will be available online immediately following successful completion of the activity.

INSTRUCTIONS TO RECEIVE CREDIT
Please complete the pre-test, listen to and watch the following presentation, and complete the post-test and evaluation to receive CPE credit for this activity. A statement of credit will be available online immediately following successful completion of the activity.

TABLE OF CONTENTS
Pre-assessment

Overview and Goals
Chris Fausel, PharmD, MHA, BCOP

NCCN Guidelines for Response Assessment
Chris Fausel, PharmD, MHA, BCOP

Therapy Adjustments Based on Molecular Response
Chris Fausel, PharmD, MHA, BCOP

Pharmacogenetics of CML: Personalizing CML Treatment
R. Donald Harvey, PharmD, FCCP, BCOP

Case Studies
Chris Fausel, PharmD, MHA, BCOP, and R. Donald Harvey, PharmD, FCCP, BCOP

Discussion and Q & A
Chris Fausel, PharmD, MHA, BCOP, and R. Donald Harvey, PharmD, FCCP, BCOP

Post-assessment

Submit a case to review at event:


procced to pretest


spacer  
  spacer
Advanced Studies in Medicine © 2014 Contact Us
spacer  
spacer